Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Massachusetts General Hospital | OTHER |
| Stanford University | OTHER |
| Harvard School of Public Health (HSPH) | OTHER |
Not provided
Not provided
Not provided
The PREDICT 3 study will build on previous research in over 2,000 individuals to further refine machine learning models that predict individual responses to foods, with the aim of advancing precision nutrition science and individualized dietary advice. The study incorporates both standardized and controlled dietary intervention, for the purpose of testing postprandial responses to specific mixed meals, in addition to a free-living period with a dietary record for measuring responses to a large variety of meals consumed in a realistic context, where the role of external factors (e.g. exercise, sleep, time of day) on postprandial responses may be determined. For the first time this PREDICT study is built on top of a commercial product which will allow access to a much larger group of participants who are already collecting large amounts of data through digital and biochemical devices that can contribute to science.
Choice of design: The study is a single arm mechanistic intervention study.
Study population: The subject must have enrolled in the commercial ZOE testing program in order to apply for participation in the PREDICT 3 research program.
Screening Assessment: The study eligibility criteria listed below closely match to the commercial eligibility criteria, which ZOE users consent to before enrolling in the commercial program.
Study duration: Each participant will take part in the study for 6-14 days.
Dietary intervention: The dietary intervention will be carried out on up to 6 days with the option to continue monitoring for a total study period of 14-days. On day one, participants will be asked to fit glucose monitor. Over the following consecutive days, each participant will be instructed to eat 2 standardized meals. Participants are free to eat whatever they wish at all other times. The standardized meals will be provided to all participants by the study team via post. The foods included as part of these meals will be foods that are commonly consumed and can be made from products sold in US supermarkets. Participants will be asked to consume the entire amount of food indicated for the standardized meals and to record any left-over food via a digital app for which training will be provided at the start of the study. Following completion of standardized meal period, participants are free to eat and drink whatever they wish and will be asked to track all meals, snacks and drinks on their digital app. Participants will also be advised not to change their physical activity patterns during the course of the study.
Regular contact will be made with the participants via phone, their app and text messages for the period of the intervention to encourage compliance and answer any queries.
Anthropometry: The participant will be instructed to report height and weight.
Dietary and Lifestyle: Participants will be asked to complete a baseline questionnaire online, as well as a diet history questionnaire with portion sizes about the month preceding their study period. They will be asked to record on a daily basis their dietary, activity, and psychological data (e.g. hunger) using a digital mobile phone app. Training in all apps and equipment will be given through written and online instructions and via communications with the study support staff.
Digital devices: Participants will be asked to record daily dietary and activity information using digital apps and lifestyle information will be monitored using a wearable device. The continuous glucose monitor (Freestyle Libre, CGM) provides continuous glucose profiles for up to 14 days. The CGM will be inserted on the back of the upper arm, one day before participants begin dietary intervention. This will measure subcutaneous interstitial fluid glucose concentrations every 5 minutes. The CGM will be removed at the end of the intervention period by the participant. A contact number will be made available to participants for any inquiries or if any problems arise. Data from the CGM will be downloaded, and glucose profiles will be evaluated on the basis of data collected.
Meal responses: As a product user, the participant will consume standardized meals an additional day to the study intervention.
Blood samples: As a product user, the participant will collect postprandial blood on 1 day using finger-prick blood sampling.
Stool sample: As a product user, the participant will collect a stool sample on 1 day.
Digital app: As product users, participants will be asked to download an app designed specifically for this study, which provides diet logging functionality similar to widely used existing apps such as MyFitnessPal.
Participants will be asked to record and monitor the following information via the digital app:
The app will be available in versions for iOS operating systems. The app will synchronize remotely with backend database servers, over an encrypted and authenticated API, and will support offline operation for when patients wish to record an entry without network coverage. This continuous background synchronization means that it will not be necessary to explicitly download data from the phone at the end of the study.
Following the 2020 pandemic of COVID-19, participants are asked to use the COVID-19 Symptom Tracker app to record their physical health symptoms, or lack thereof, attributable to COVID-19, as well as demographic and other health information to track the spread of disease in real time, and to potentially reveal risk factors for infection and severe illness.
Subcohort: An opt-in follow-on study will be offered to participants to follow dietary guidance from the ZOE app based on their PREDICT 3 results. During the first 4 weeks, participants will be given dietary guidance to follow from the ZOE app. Thereafter, for a period of up to 12 months, participants will be asked to report on outcome measures at regular intervals (monthly). Outcome measures will be reported before, during and after the 4 week period and include weight, bristol stool chart, bowel habits, hunger, energy, adherence to dietary advice, and app usage. Participants (UK only) will collect additional stool samples at variable intervals.
The data will be used to test the efficacy of the ZOE dietary advice in promoting weight loss and improvement of overall health, and may be stratified by age, sex, BMI, adherence and/or motivation to take part in the PREDICT 3 study.
Food Frequency Questionnaire Validation: A food-frequency questionnaire (FFQ) developed using the most frequently logged foods within the ZOE app will be validated against a 4-day period of food logging in the app as well as the commonly used US-based DHQ3 FFQ (target enrollment; n=100).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dietary Intervention | Experimental | Dietary intervention using standardized test meals after which the postprandial metabolic response is measured. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dietary Intervention | Other | To carry out a dietary intervention using standardized test meals, where the participant's postprandial response to the meal is measured and is used to predict their postprandial responses to other foods, along with input variables including metabolic profile, anthropometry, sleep and exercise. |
| Measure | Description | Time Frame |
|---|---|---|
| Glucose | Measurement of blood glucose by continuous glucose monitor (mmol/L) | 6-14 days |
| Gut microbiome species richness | Species count in fecal sample (as part of ZOE testing program) | 1 day |
| Blood Lipids | Measurement of baseline and 6-h post-prandial triglycerides (mmol/L) by dried blood sample (as part of ZOE testing program) | 1 day |
| Hunger and appetite assessment | Self-reported in-app question on energy levels (categorical) (as part of ZOE testing program) | 6-14 days |
| Glucose and HbA1c | Measurement of baseline glucose (mmol/L) and HbA1c (%) by dried blood sample (as part of ZOE testing program) | 2 days |
| Measure | Description | Time Frame |
|---|---|---|
| Dietary assessment | Weighed food log | 6-14 days |
| Anthropometry | Weight (kg) (as part of ZOE testing program) | 1 day |
| Measure | Description | Time Frame |
|---|---|---|
| Adherence (in sub-cohort) | Self-reported in-app question on daily frequency of adherence (categorical) | Time Frame: 12 months: Baseline, Weekly (0 to 4 weeks), monthly (5 to 52 weeks) |
| Hunger (in sub-cohort) |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Meaghan Reardon | Contact | 866-771-7478 | meaghan@joinzoe.com | |
| Dan Sleeper | Contact | 866-771-7478 | dan@joinzoe.com |
| Name | Affiliation | Role |
|---|---|---|
| Tim Spector, PhD | Zoe Global Limited | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Zoe US Inc. | Recruiting | Needham | Massachusetts | 02494 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D006331 | Heart Diseases |
| D005247 | Feeding Behavior |
| D009765 | Obesity |
| D003141 | Communicable Diseases |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D004035 | Diet Therapy |
| ID | Term |
|---|---|
| D044623 | Nutrition Therapy |
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Anthropometry | Height (cm) (as part of ZOE testing program) | 1 day |
| Dietary assessment | Diet history and portion size questionnaire about the preceding month (as part of ZOE testing program) | 1 month |
| Bowel Type and Habit | Measurement by Bristol Stool Chart and Questionnaire (as part of ZOE testing program) | 6-14 days |
| Perceived Energy Assessment | Self-reported in-app question on energy levels (categorical) (as part of ZOE testing program) | 6-14 days |
| Covid-19 symptom assessment | Self-reported demographic and physical health symptoms, or lack thereof, reported on a daily basis (as part of ZOE testing program) | 6 months |
Self-reported in-app question on hunger levels (categorical)
| Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks) |
| Weight (in sub-cohort) | Body Weight (kg) | Time Frame: 12 months: Baseline, Weekly (0 to 4 weeks), monthly (5 to 52 weeks) |
| Bristol Stool Category (in sub-cohort) | Self-reported in-app Bristol Stool chart question (categorical) | Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks) |
| Bowel Frequency (in sub-cohort) | Self-reported in-app question on bowel frequency | Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks) |
| Energy (in sub-cohort) | Self-reported in-app question on energy levels (categorical) | Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks) |
| Waist Circumference (in sub-cohort) | Self-reported in-app question on waist circumference | Time Frame: 12 months: Baseline, monthly (4 to 52 weeks) |
| Hip Circumference (in sub-cohort) | Self-reported in-app question on hip circumference | Time Frame: 12 months: Baseline, monthly (4 to 52 weeks) |
| King's College London | Recruiting | London | United Kingdom |
|
| D002318 | Cardiovascular Diseases |
| D001522 | Behavior, Animal |
| D001519 | Behavior |
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D007239 | Infections |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |